【摘要】 为了探讨新型反应性氧代谢物(reactiveoxygenmetabolites,ROM)清除剂在NK细胞抑制K562细胞时作为免疫佐剂的作用,采用IL-2及PHA活化单核(MO)细胞,使MO细胞的ROM产量增加,观察NK细胞活性和K562细胞抑制率(KIR)的相应变化,然后在不同比例的MO+NK+K562细胞培养体系中加入不同浓度的ROM清除剂(硫普罗宁),定期检测ROM产量及KIR(每种检测均做3个复孔),同时应用不同浓度的二氢氯组胺(DHT)作为阳性对照。结果表明:在K562细胞、NK细胞混合培养体系中,当E/T=10/1时,加入IL-2/PHA后ROM的产量从33.17±25.02U/ml增至223.59±59.41U/ml(P<0.05),KIR从65.56%升至85.89%(P<0.05);当按E/MO=10/2、10/5、10/10三种比例加入MO细胞后,ROM产量随着MO细胞数量的增加而增加(ROM产量分别为389.79±43.83U/ml,456.74±42.77U/ml,601.42±21.92U/ml),而KIR则相反(KIR分别为82.36%,81.36%,48.09%);而在K562+NK+MO+IL-2/PHA混合培养体系中加入硫普罗宁、DHT后,当E/MO=10/2时,ROM产量从389.79±43.83U/ml分别降至-1.20±60.70U/ml和50.21±22.4U/ml(P<0.05),KIR则从82.53%分别升至96.09%和94.64%(P<0.05)。随着硫普罗宁、DHT浓度的增加,ROM产量逐渐减少。ROM产量与KIR呈负相关(r=-0.518)。当E/MO为10/5或10/10时,各浓度硫普罗宁及高浓度的DHT可使ROM产量减少(P<0.05),但KIR提高不明显(P>0.05)。硫普罗宁在提高KIR的效应方面与DHT相似(P>0.05),而在清除ROM方面,硫普罗宁较DHT为优(P<0.05)。结论:①MO细胞是ROM产生的最主要来源,其产生的ROM可使NK细胞的抗瘤(抗K562)活性下降;②新型ROM清除剂(硫普罗宁)可有效清除ROM,在一定程度上逆转ROM对NK细胞抗K562细胞的抑制作用,且在逆转ROM方面优于DHT,在提高NK细胞对K562细胞的抑制率方面效应强度与DHT相似,但毒副作用较低,有望替代DHT作为免疫佐剂用于白血病的过继性免疫治疗中。更多还原

【Abstract】 To investigate the effect of a new reactive oxygen metabolites (ROM) scavenger as immune adjuvant in NK cell-mediated killing effect on K562 cell, IL-2 and PHA were used to activate monocyte to produce ROM, and different concentrations of tiopronin as ROM scavenger was used in the cultivated systems with different ratio of monocytes plus NK cells and K562 cells, while histamine dihydrochloride (DHT) with different concentrations was used as positive control. The reuslts indicated that after IL-2 and PHA were supplemented in the cultivated systems mixing with NK cells and K562 cells as the E/T ratio was 10/1, the ROM production increased from 33.17±25.02 U/ml to 223.59±59.41 U/ml (P<005) while K562 cell inhibition rate (KIR) increased from 65.56% to 85.89% (P<005). When the monocytes as the E/MO ratios of 10/2, 10/5 and 10/10 were supplemented respectively, ROM production increased correspondingly (ROM production was 389.79±43.83 U/ml, 456.74±42.77 U/ml, 601.42±21.92 U/ml, respectively), and KIR was on the other round (KIR was 82.36%, 81.36%, 48.09% respectively). Tiopronin, DHT were used in the K562+ NK+MO+IL-2/PHA cultivated systems as the E/MO ratio was 10/2, the ROM production also decreased from 389.79±43.83 U/ml to -1.20±60.70 U/ml, 50.21±22.4 U/ml (P<0.05) , respectively, however KIR increased from 82.53% to 96.09% and 94.64% either (P<0.05). Higher concentrations of tiopronin and DHT were used, ROM production decreased accordingly. There showed a reverse correlation between ROM production and KIR (r=-0.518). When E/MO ratio was 10/5 or 10/10, tiopronin at any testing concentration and DHT at the higher testing concentration could reduce the ROM production (P<0.05), but did not improve KIR significantly (P>0.05). Tiopronin was as good as DHT in ameliorating KIR (P>0.05) and better than DHT in scavenging ROM (P<0.05). It is concluded that (1) Monocytes are the major resources of ROM, and the ROM derived from monocytes can disable NK cells in killing neoplasm cells (K562 cells); (2) A new ROM scavenger, tiopronin, can scavenge ROM effectively, and reverse the ROM induced inhibition of NK cell-mediated killing of K562 cell in a certain extent. And tiopronin is better than DHT in scavenging ROM, and as good as DHT in up-regulating KIR. The new ROM scavenger tiopronin with less side effect may take the place of DHT as adjuvant during the adoptive immuno-therapy in leukemia.更多还原